Kalaris Therapeutics Reports $22.4 Million Net Loss and Cash Reserves of $93.5 Million

Kalaris Therapeutics, Inc. reported a net loss of $22.4 million for the six months ended June 30, 2026, compared to a loss of $21.5 million for the same period in 2025. The company's total operating expenses increased to $24.2 million from $22.6 million year-over-year, primarily driven by a rise in research and development costs, which grew from $14.5 million to $16.6 million. General and administrative expenses decreased slightly from $8.1 million to $7.6 million. The company has not generated any revenue from product sales, maintaining an accumulated deficit of $182.4 million as of June 30, 2026.

In terms of financial position, Kalaris reported cash, cash equivalents, and marketable securities totaling $93.5 million as of June 30, 2026, a decrease from $118.8 million at the end of 2025. The decline in cash reserves was attributed to significant cash outflows from operating activities, which amounted to $22.6 million in the first half of 2026. The company also engaged in investing activities that resulted in a net cash outflow of $30.2 million, primarily due to purchases of marketable securities. Kalaris anticipates that its current cash position will be sufficient to fund operations into the fourth quarter of 2027, although it may require additional funding to support ongoing clinical trials and operational costs.

Strategically, Kalaris is focused on advancing its lead product candidate, TH103, a treatment for neovascular age-related macular degeneration (nAMD). The company recently announced positive data from its Phase 1a clinical trial, indicating that TH103 was well tolerated and showed promising efficacy. Kalaris is currently conducting a Phase 1b/2 multiple ascending dose clinical trial for TH103, with plans to initiate Phase 3 trials by the end of 2027, pending favorable results. The company is also exploring the expansion of TH103's application to other retinal diseases.

Kalaris underwent a significant organizational change following its merger with AlloVir, which was completed on March 18, 2025. This merger resulted in Kalaris becoming a wholly-owned subsidiary of AlloVir, with the combined entity now trading under the ticker symbol "KLRS" on the Nasdaq Global Market. The merger has provided Kalaris with additional resources, including approximately $102.1 million in cash and cash equivalents from AlloVir, which has been instrumental in funding its ongoing operations.

Looking ahead, Kalaris acknowledges the need for substantial additional funding to continue its operations and product development. The company plans to monitor expenses closely and may pursue a combination of equity and debt financing, strategic alliances, and licensing arrangements to secure the necessary capital. The management remains cautious about the potential impact of macroeconomic factors, including inflation and geopolitical tensions, on its financial position and operational plans.